Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Financings Of The Fortnight Expects An Increase In Life Sciences IPOs In 2013

Feb 08 2013

• By Alex Lash, Lisa LaMotta, and John Davis

Related Content

Reading Into Pfizer's Changes: First Steps For New CEO

Feb 07 2011

Bristol Flying Solo As A Pure Biopharma After Mead Johnson Spin Out

Nov 16 2009

Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High

Jan 07 2013

Bone Therapeutics Raises $10.4M To Speed Phase III Cell Therapy Trials

Jan 28 2013

Ariad Prepares For Early Launch Of CML Drug Ponatinib

Aug 06 2012

Tarsa Raises $28 Million Series B to Support Regulatory Filings of Oral Calcitonin

Mar 16 2012

Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead

Nov 15 2012

Reinventing Cell Therapy And Biomaterials

Jan 25 2013

Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE

Feb 01 2013

Related Companies

Verastem, Inc.

Adocia

Melinta Therapeutics, Inc.

ChemoCentryx, Inc.

Humanigen, Inc.

Stemline Therapeutics, Inc.

Pfizer Inc.

IQVIA Holdings Inc.

Lonza Group AG

Nestle Health Science

Bristol Myers Squibb Company

Mead Johnson Nutrition Co.

Takeda Pharmaceutical Co. Ltd.

ARIAD Pharmaceuticals, Inc.

Sanofi Genzyme

Talphera, Inc.

Intarcia Therapeutics, Inc.

Keryx Biopharmaceuticals Inc.

Puma Biotechnology, Inc.

Solta Medical Inc

Tarsa Therapeutics, Inc.

Additional Topics

Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window